RU2006126541A - Биомаркеры чуствительности пролиферативных заболеваний к ингибиторам mtor - Google Patents

Биомаркеры чуствительности пролиферативных заболеваний к ингибиторам mtor Download PDF

Info

Publication number
RU2006126541A
RU2006126541A RU2006126541/15A RU2006126541A RU2006126541A RU 2006126541 A RU2006126541 A RU 2006126541A RU 2006126541/15 A RU2006126541/15 A RU 2006126541/15A RU 2006126541 A RU2006126541 A RU 2006126541A RU 2006126541 A RU2006126541 A RU 2006126541A
Authority
RU
Russia
Prior art keywords
mtor inhibitor
proliferative disease
subject
treatment
sensitivity
Prior art date
Application number
RU2006126541/15A
Other languages
English (en)
Inventor
Анне БУЛАЙ (FR)
Анне БУЛАЙ
Хайди ЛАНЕ (CH)
Хайди Лане
Совэ-Мишель МАЙРА (FR)
Совэ-Мишель МАЙРА
Теренс О`РЕЙЛЛИ (CH)
Теренс О`РЕЙЛЛИ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2006126541A publication Critical patent/RU2006126541A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (17)

1. Применение S6 в качестве биомаркера для определения чувствительности пролиферативного заболевания субъекта к лечению ингибитором mTOR.
2. Применение S6 в качестве биомаркера с целью отбора субъектов больных пролиферативным заболеванием для лечения ингибитором mTOR.
3. Применение по п.1 или 2, включающее применение уровня экспрессии и/или состояния фосфорилирования S6.
4. Применение по п.1 или 2, включающее использование уровня экспрессии фосфорилированного белка S6.
5. Применение по любому из п.1 или 2, при котором пролиферативное заболевание является раком.
6. Применение по одному из п.1 или 2, при котором ингибитор mTOR является рапамицином или производным рапамицина.
7. Применение по одному из п.1 или 2, при котором производное рапамицина является 40-О-(2-гидроксиэтил)рапамицином.
8. Применение по одному из п.1 или 2, при котором повышенная экспрессия фосфорилированного белка S6 относительно контроля является прогнозом чувствительности пролиферативного заболевания к лечению ингибитором mTOR.
9. Способ определения чувствительности пролиферативного заболевания субъекта к лечению ингибитором mTOR, включающий определение уровня экспрессии и/или состояния фосфорилирования S6 в образце, взятом у субъекта.
10. Способ по п.9, в котором пролиферативное заболевание является раком.
11. Способ по п.9, в котором ингибитор mTOR является рапамицином или производным рапамицина.
12. Способ по п.9, в котором производное рапамицина является 40-О-(2-гидроксиэтил)рапамицином.
13. Способ по п.9, включающее установление уровня экспрессии фосфорилирования белка S6.
14. Способ по п.9, в котором образец берется из раковой опухоли субъекта.
15. Способ по п.9, в котором повышенная экспрессия фосфорилированного белка S6 относительно контроля является прогнозом чувствительности пролиферативного заболевания к лечению ингибитором mTOR.
16. Способ выбора субъектов больных пролиферативным заболеванием для лечения ингибитором mTOR, включающий определение чувствительности пролиферативного заболевания к лечению ингибитором mTOR у каждого субъекта способом, описанным в п.9, и выбор тех субъектов, которые показали повышенную экспрессию фосфорилированного S6, для лечения ингибитором mTOR.
17. Способ лечения пролиферативного заболевания субъекта, нуждающегося в этом, включающий определение уровня экспрессии фосфорилированного S6 в образце, взятом у субъекта, способом, описанным в п.9, и лечение субъекта ингибитором mTOR, если уровень экспрессии фосфорилированного S6 повышен.
RU2006126541/15A 2003-12-22 2004-12-21 Биомаркеры чуствительности пролиферативных заболеваний к ингибиторам mtor RU2006126541A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53170003P 2003-12-22 2003-12-22
US60/531,700 2003-12-22

Publications (1)

Publication Number Publication Date
RU2006126541A true RU2006126541A (ru) 2008-01-27

Family

ID=34738681

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006126541/15A RU2006126541A (ru) 2003-12-22 2004-12-21 Биомаркеры чуствительности пролиферативных заболеваний к ингибиторам mtor

Country Status (11)

Country Link
US (2) US20070167478A1 (ru)
EP (1) EP1709449A1 (ru)
JP (1) JP2007519897A (ru)
KR (1) KR20060123367A (ru)
CN (1) CN1898568A (ru)
AU (1) AU2004309499A1 (ru)
BR (1) BRPI0418022A (ru)
CA (1) CA2549829A1 (ru)
MX (1) MXPA06007174A (ru)
RU (1) RU2006126541A (ru)
WO (1) WO2005064343A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CA2626456C (en) 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
JP2009516671A (ja) 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
RU2609208C2 (ru) * 2011-10-07 2017-01-31 Селлзоум Лимитед МОРФОЛИНО-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ БИЦИКЛИЧЕСКИХ ПИРИМИДИНМОЧЕВИНЫ ИЛИ КАРБАМАТА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046471A2 (en) * 2000-12-08 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions for the identification, assessment and therapy of human cancers
US6969592B2 (en) * 2001-09-26 2005-11-29 Pharmacia Italia S.P.A. Method for predicting the sensitivity to chemotherapy
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
JP2003180368A (ja) * 2001-12-19 2003-07-02 Pharma Design Inc 癌患者に対する放射線治療の有効性の予測方法
AU2003268135A1 (en) * 2002-08-15 2004-03-19 Functional Genetics, Inc. Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes
JP2006505793A (ja) * 2002-11-05 2006-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膠芽腫の進行に関連する経路を試験するための方法及び材料

Also Published As

Publication number Publication date
US20070167478A1 (en) 2007-07-19
EP1709449A1 (en) 2006-10-11
AU2004309499A1 (en) 2005-07-14
KR20060123367A (ko) 2006-12-01
CA2549829A1 (en) 2005-07-14
JP2007519897A (ja) 2007-07-19
CN1898568A (zh) 2007-01-17
US20080214596A1 (en) 2008-09-04
MXPA06007174A (es) 2006-08-23
WO2005064343A1 (en) 2005-07-14
BRPI0418022A (pt) 2007-04-17

Similar Documents

Publication Publication Date Title
JP2010510784A5 (ru)
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
Chen et al. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis
WO2005117553A3 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
RU2006133828A (ru) Биомаркеры
WO2005010486A3 (en) Biomarker panel for colorectal cancer
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
JP2006523452A5 (ru)
EP2011885A3 (en) Method of diagnosing bladder cancer
Park et al. Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EP1953549A4 (en) ASBESTAN PROCEDURE, ASBESTAN DETERGENT, ASBESTAT PROTECTION KIT, AND METHOD FOR SEARCHING FOR CANDIDATES FOR A MEDICAMENT TO PREVENT OR TREAT ANY DISEASE OR CLAIMED ASBEST DISEASE
JP2014521089A5 (ru)
DE602005008013D1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
WO2012040602A3 (en) Targeting mtor substrates in treating proliferative diseases
JP2014505877A5 (ru)
RU2006126541A (ru) Биомаркеры чуствительности пролиферативных заболеваний к ингибиторам mtor
RU2013148768A (ru) Способы предсказания и улучшения выживаемости пациентов с раком желудка
RU2007129864A (ru) Фармакогеномные маркеры для прогнозирования солидных опухолей
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
CN104267191A (zh) 口腔口咽鳞状细胞癌的生物标志物及其应用
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
CN112041025A (zh) 用于进行头部照射的光治疗设备及光治疗仪及其治疗方法
Trovo et al. Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090428